摘要
采用溴代琥珀酰亚胺法制备利卡汀（^131I-肝癌单抗片段HAb18 F（ab’）2注射液）后,将其插至肝固有动脉或肿瘤的供血肝动脉的导管注入受试者体内,并在给药后不同时刻进行全身显像,用感兴趣区技术测定受试者组织的放射性计数率,计算受试者组织的放射性药物摄取率及肝肿瘤组织与非瘤组织的放射性摄取比（T/NT）,以观察药物在各组织及肿瘤内分布的动态变化。结果显示：利卡汀在肝癌组织中有明显的摄取,早期主要浓聚于肝癌组织及肝组织中,体内其他组织的浓聚甚少;随着时间的延长,肝癌组织的放射性浓聚相对于肝组织持续增强,而肝组织的放射性逐渐减少;在显像期间（192 h）,除肝外,其他正常组织的T/NT为1.04～3.79,而肝脏的T/NT随时间延长而增加,至192 h时为1.09。以上结果表明,利卡汀能特异性结合肝癌组织。
Imaging and biodistribution of Licartin （^131I-labeled hepatoma monoclonal antibody HA1l8 F（ab＇）2） were assessed in vivo. Licartin was prepared using N-bromosuccinimide （NBS） labeling method, and was injected into the patients with primary hepatocelluar carcinoma （HCC） by the hepatic artery. Every patient was carried out whole body imaging at different time after injection. The uptake of every tissue and the ratios of tumor tissue and non-tumor tissue （T/NT） were calculated using region of interest technique in order to observe the dynamic change of drug distribution in every tissue or tumor. The research resuits show that Licartin mainly accumulates in liver cancer and liver tissue and a small amount of that accumulates in other tissue, the radioactive concentration continuously increases in liver cancer and the uptake of radioactivity gradually decreases in liver with the extension of time. During the imaging time period （192 h ）, T/NT of other normal tissue besides liver are 1.04 -3.79, but T/NT of liver gradually increase as the time increas by 1.09 at 192 h. Therefore, HCC can specifically combine with Licartin.
出处
《同位素》
CAS
北大核心
2007年第3期135-139,共5页
Journal of Isotopes
